Concepedia

Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience

Phoebe A. Tsao, Jason P. Estes, Jennifer J. Griggs, David C. Smith, Megan E.V. Caram

Clinical Genitourinary Cancer · 2019 · 16 citations · 28 references

Concepts

PharmacyOncologyPharmacologyCardiovascular PharmacotherapyPharmacodynamicsProstate DiseaseCardiotoxicity ManagementCardiovascular Drug SafetyProstate CancerToxicity ClassificationToxicity ManagementToxicity Risk AssessmentAndrogen Therapy Adverse EffectsAndrogenic ToxicityCardiovascular Drug ToxicityCardiovascular Toxicity AssessmentCastration-resistant Prostate Cancer TherapyHormone Therapy ToxicityProstate Cancer Hormone Therapy

References

28

Heart Disease and Stroke Statistics—2016 Update

Dariush Mozaffarian, Emelia J. Benjamin, Alan S. Go et al. · Circulation · 2015 · 6.6K citations

Medicine, Cardiology, Internal Medicine +11

Bias reduction of maximum likelihood estimates

David Firth · Biometrika · 1993 · 4.4K citations

Business, Biostatistics, Bayesian Biostatistics +16

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +17

External validity of randomised controlled trials: “To whom do the results of this trial apply?”

Peter M. Rothwell · The Lancet · 2005 · 2.5K citations

Public Health, Biostatistics, Evidence-based Practice +12